Compare SCLXW & SLDPW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCLXW | SLDPW |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | 34 | 230 |
| Industry | Biotechnology: Pharmaceutical Preparations | Electrical Products |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | SCLXW | SLDPW |
|---|---|---|
| Price | $0.20 | $0.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.9K | ★ 32.8K |
| Earning Date | 03-07-2025 | 02-27-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $55,152,000.00 | $18,026,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.02 | N/A |
| 52 Week Low | $0.05 | $0.08 |
| 52 Week High | $0.64 | $2.33 |
| Indicator | SCLXW | SLDPW |
|---|---|---|
| Relative Strength Index (RSI) | 57.69 | 36.64 |
| Support Level | $0.11 | N/A |
| Resistance Level | $0.21 | $0.28 |
| Average True Range (ATR) | 0.02 | 0.02 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 92.12 | 6.12 |
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Solid Power Inc develops solid-state battery technology and manufacturing processes. Its sulfide-based solid electrolyte material replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells and enables improvement in energy density, battery life and safety performance. The company produces electrolytes on two pilot manufacturing lines using a batch manufacturing process for customer sampling and internal cell development, and manufactures solid-state cells on pre-pilot and pilot cell manufacturing lines. Its cell manufacturing processes are developed around industry-standard lithium-ion battery manufacturing processes and equipment, and it manufactures all cell designs, including cathodes and anodes, using materials sourced from external suppliers.